Oxford University Innovation Limited;The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services
发明人:
VEECH, Richard, Lewis,CLARKE, Kieran
申请号：
DK09701051
公开号：
DK2240017T3
申请日:
2009.01.05
申请国别(地区):
DK
年份:
2019
代理人:
摘要：
The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic &bgr；-hydroxybutyrate or D-&bgr；-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic &bgr；-hydroxybutyrate or D-&bgr；-hydroxybutyrate, esters of D-&bgr；-hydroxybutyrate, oligomers of D-&bgr；-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic &bgr；-hydroxybutyrate or D-&bgr；-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic &bgr；-hydroxybutyrate or D-&bgr；-hydroxybutyrate, esters of D-&bgr；-hydroxybutyrate, oligomers of D-&bgr；-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or combinations thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions containing a) anti-hypertensive agents； b) anti-inflammatory agents； c) glucose lowering agents； or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels； triglyceride levels； serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and/or hypertension in treated subjects. Alternatively, compositions disclosed herein can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease.
